Trial Profile
Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 04 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Sep 2014 According to ClinicalTrials.gov record, planned End Date changed from 1 Dec 2015 to 1 Nov 2015.
- 18 Sep 2014 According to ClinicalTrials.gov record, planned primary completion date changed from 1 Jan 2015 to 1 Nov 2013.